

**FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICE**

Applicants Docket Number:  
DEAV2002/0094 US CNT

Applicants:  
KLEEMANN, et al.

Serial No.  
10/749,631

Filing Date:  
December 31, 2003

Title of Invention:  
3-Guanidinocarbonyl-1-heteroaryl-indole Derivatives, Preparation process, Their Use as Medicaments, and  
Pharmaceutical Compositions Comprising Them

**CERTIFICATE OF TRANSMISSION**  
I hereby certify that this correspondence is being transmitted via  
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,  
VA 22313-1450, at 703 746-9193, on  
Date of Deposit September 7, 2004  
Printed Name of Person Signing Certificate Renee McGinnis  
Signature Renee McGinnis

Total Number of Pages Sent: 11

Attorney: Raymond S. PARKER, III

Group Art Unit: 1626

Examiner:

TO: Mail Stop Office of Initial Patent Examination's Filing Receipt Corrections  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet,  
signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit  
account (18-1982) in the name of Aventis Pharmaceuticals Inc.

- |  |   |
|--|---|
| <input type="checkbox"/> Amendment, 37 CFR _____               | <input type="checkbox"/> Fee Transmittal  |
| <input type="checkbox"/> Charge deposit account, in duplicate  | <input type="checkbox"/> Petition under 37 CFR _____  |
| <input type="checkbox"/> Extension of Time Petition            | <input checked="" type="checkbox"/> Other <u>Request for Corrected Filing Receipt</u>           |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input checked="" type="checkbox"/> Other <u>Copy of Updated Filing Receipt dated 7/19/2004</u> |
| <input type="checkbox"/> Maintenance Fee Transmittal           | <input checked="" type="checkbox"/> Other <u>Copy of Filing Receipt dated 03/23/2004</u>        |
|  | <input checked="" type="checkbox"/> Other <u>Copy of Application Data Sheet</u>                 |

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com  
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this  
telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**KLEEMANN, et al.**

Examiner:

Application No.: **10/749,631**

Art Unit: **1626**

Filed: **December 31, 2003**

Title: **3-Guanidinocarbonyl-1-heteroaryl-indole  
Derivatives, Preparation process, Their  
Use as Medicaments, and  
Pharmaceutical Compositions  
Comprising Them**

**TELEFAX CERTIFICATE**

I hereby certify that this correspondence is being  
transmitted via facsimile to the Commissioner for  
Patents, Alexandria, VA 22313, at 703 746-9195, on

September 7, 2004  
Date of Transmission

Renee McInnis  
Signature

**REQUEST FOR CORRECTED FILING RECEIPT**

Mail Stop Office of Initial Patent Examination's Filing Receipt Corrections  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450


Attached is copy of the official Updated Filing Receipt from the Patent and Trademark Office  
in the above-identified application, for which issuance of a corrected filing receipt is respectfully  
requested.

There is an error in the Applicant(s) section. Applicant "Jean Bouquerel's name is  
incorrectly spelled. It should read as follows – Jean Bouquerel, not Bouoquerel.

A copy of the official Filing Receipt dated 03/23/2004, is attached which reflects the correct  
spelling of the name. In addition, a copy of the Application Data sheet is attached showing the  
correct spelling of the name.

Please note the error is not due to the Applicant, and no fee should be required.

Respectfully submitted,

  
Raymond S. Parker, III, Ph.D., Reg. No. 34/893  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-5674  
Telefax (908) 231-2626

Aventis Docket No. DEA V2002/0094 US CNT



UNITED STATES PATENT AND TRADEMARK OFFICE

COPY

 UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22304-1450  
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/749,631	12/31/2003	1626	1404	DEAV2002/0094 US CNT			

CONFIRMATION NO. 8300

UPDATED FILING RECEIPT

  
 \*OC000000013258986\*

 05487  
 ROSS J. OEHLER  
 AVENTIS PHARMACEUTICALS INC.  
 ROUTE 202-206  
 MAIL CODE: D303A  
 BRIDGEWATER, NJ 08807

Date Mailed: 07/19/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Heinz-Werner Kleemann, Bischofsheim, GERMANY;  
 Jean-Christophe Carry, Saint Maur des Fosses, FRANCE;  
 Pascal Desmazeau, Tigery, FRANCE;  
 Serge Mignani, Chateauf-Malabry, FRANCE;  
 → Jean Bouquere, Drancy, FRANCE;  
 Arielle Genevois-Borella, Thiais, FRANCE;  
 Baptiste Ronan, Clamart, FRANCE;

## Assignment For Published Patent Application

AVENTIS PHARMA DEUTSCHLAND GmbH, Frankfurt am Main, GERMANY;

## Domestic Priority data as claimed by applicant

This application is a CON of PCT/EP03/07023 07/02/2003

## Foreign Applications

FRANCE FR 0208948 07/16/2002

If Required, Foreign Filing License Granted: 03/23/2004

Projected Publication Date: 10/28/2004

Non-Publication Request: No

ACTION DUE	Comments
DUE DATE	7-22-04
DKTD BY	RSP/Venne-Dunkel
ATTY	

**Early Publication Request:** No

**Title**

3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them

**Preliminary Class**

514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (f)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



# COPY

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/749,631	12/31/2003	1626	1274	DEAV20020094USCNT		48	

CONFIRMATION NO. 8300

05487  
ROSS J. OEHLER  
AVENTIS PHARMACEUTICALS INC.  
ROUTE 202-206  
MAIL CODE: D303A  
BRIDGEWATER, NJ 08807

## FILING RECEIPT

\*OC00000001216555Z\*

Date Mailed: 03/23/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Heinz-Werner Kleemann, Bischofsheim, GERMANY;  
Jean-Christophe Carry, Saint Maur des Fosses, FRANCE;  
Pascal Desmazeau, Tigery, FRANCE;  
Serge Mignani, Chateauf-Malabry, FRANCE;  
→ Jean Bouquerel, Drancy, FRANCE;  
Anelle Genevois-Borella, Thiais, FRANCE;  
Baptiste Ronan, Clamart, FRANCE;

ACTION DUE

*Send filing receipt  
forth letter*

DUE DATE

*5-9-04*

DKTD BY

*Ry 3-26-04*

ATTY

*RSP/Vonne-Duncker*

## Assignment For Published Patent Application

AVENTIS PHARMA DEUTSCHLAND GmbH, Frankfurt am Main, GERMANY;

## Domestic Priority data as claimed by applicant

This application is a CON of PCT/EP03/07023 07/02/2003

## Foreign Applications

FRANCE FR 0208948 07/16/2002

If Required, Foreign Filing License Granted: 03/23/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

**Early Publication Request: No**

**Title**

3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them

**Preliminary Class**

514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).